查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933275

全球再生医学市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Regenerative Medicine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 192 Pages | 商品交期: 请询问到货日

价格

再生医学市场成长因素

受细胞疗法、基因疗法、组织工程和富血小板血浆（PRP）疗法等创新技术的推动，全球再生医学市场预计将快速成长。再生医学专注于利用细胞、组织或遗传物质来修復、替换或再生受损的组织和器官。 它为包括癌症、帕金森氏症、阿兹海默症、糖尿病、心血管疾病和肾臟病在内的慢性病和末期疾病提供了潜在的治疗方案。

根据 Fortune Business Insights 预测，该市场规模预计将在 2025 年达到 516.5 亿美元，2026 年增长至 630 亿美元，到 2034 年将达到 5555.8 亿美元。这意味着从 2026 年到 2034 年，其复合年增长率将高达 31.27%。北美将在 2025 年以 45.38% 的市占率引领市场，这主要得益于技术进步、细胞和基因疗法的快速普及以及有利的监管环境。预计美国市场将经历显着成长，到 2032 年将达到 1,842.1 亿美元，这主要得益于政府主导的研发计画和创新产品的批准。 市场驱动因素 研发投入增加和创新产品上市：各国政府、私人企业和学术机构都在大力投资再生医学，以开发新型疗法。例如，2022年7月，华盛顿大学获得美国国家心肺血液研究所 (NHLBI) 55.7万美元的拨款，用于推进ETRIM72蛋白的研究。该蛋白旨在再生糖尿病严重肢体缺血患者的血管和骨骼肌。同样，2022年3月，Wipro和Pandorum Technologies合作，将人工智慧融入再生医学的研发，以加速产品上市速度并改善患者预后。 新兴研发管线和临床候选药物：製药和生命科学公司正在拓展再生医学的应用领域，从伤口护理和组织修復扩展到心臟病学、肿瘤学、神经病学和罕见疾病领域。 2023年11月，希森美康公司（Sysmex Corporation）与JUNTEN BIO签署了一项免疫耐受疗法的授权协议。 2022年6月，CRISPR Therapeutics公司公布了其针对实体瘤的同种异体CAR-T细胞疗法CTX130的I期临床试验的正面结果。这些进展将促进产品的广泛应用，并加速市场成长。

慢性疾病的上升趋势：糖尿病、癌症、心血管疾病和骨科疾病发生率的上升正在推动对先进再生医学的需求。特别是，由于其在促进肌肉骨骼疾病癒合和减轻疼痛方面的有效性，预计到2026年，骨科领域将占40.61%的市场占有率。

市场限制因子

治疗费用高昂且保险覆盖范围有限：高昂的费用限制了干细胞疗法（5,000-50,000 美元）和基因疗法（如 Zolgensma，212 万美元）等治疗手段的普及。保险覆盖不足迫使患者自费或依赖众筹，阻碍了这些疗法的广泛应用。此外，缺乏针对罕见遗传疾病的核准疗法也是市场成长的一大障碍。

市场区隔

依产品分类：

  • 细胞疗法：到 2026 年，细胞疗法将占市场主导地位，市占率达 54.87%，广泛应用于自体免疫疾病、癌症、传染病和肌肉骨骼损伤的治疗。
  • 基因疗法：为脊髓性肌肉萎缩症等罕见疾病提供标靶有效的治疗方案。 该细分市场复合年增长率最高。
  • 组织工程：此细分市场占第二大市场占有率，主要利用支架、生物基质和皮肤类似物进行伤口护理。
  • 富血小板血浆 (PRP)：此细分市场市占率最小，但其在骨科和美容领域的应用正在不断扩展。

依应用领域划分：

  • 骨科：预计到 2026 年，由于骨骼和关节损伤病例的增加，该细分市场将成为最大的细分市场。
  • 肿瘤科：预计随着 CAR-T 疗法满足癌症治疗领域未被满足的需求，该细分市场将以较高的复合年增长率成长。
  • 伤口护理：由用于治疗慢性伤口的先进生物工程产品推动。
  • 罕见疾病：由于治疗选择有限且患者群体不断增长，该细分市场是成长最快的。

依最终使用者划分：

  • 医院：在外科手术和政府支持的推动下，到 2026 年将占主导地位，市占率高达 62.54%。
  • 诊所：提供专业的再生医学服务，将占第二大市场。
  • 其他：包括学术研究机构，但由于资格限制，其贡献有限。

区域概览

北美：2025 年市场规模为 234.4 亿美元，预计到 2026 年将达到 270.6 亿美元，这主要得益于再生医学技术 (RMAT) 的审批、技术应用以及强大的研发基础设施。

欧洲：第二大市场，受惠于政府资助和监管批准。 预计2026年，英国将达到35.8亿美元，德国将达到42亿美元。

亚太地区：这是成长最快的地区，预计到2026年，日本将达到35.5亿美元，中国将达到32.1亿美元，印度将达到20.1亿美元。成长的驱动因素包括慢性病的普遍流行、政府措施以及可支配收入的增加。

拉丁美洲、中东和非洲：由于医疗保健支出较低以及对治疗方法的了解有限，成长速度较慢。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 全球再生医学公司：融资状况
  • 主要国家和地区慢性病盛行率（2025 年）
  • 主要公司研发管线分析
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等
  • 再生医学技术进步医学
  • 新冠疫情对全球市场的影响

第五章 全球再生医学市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 细胞疗法
    • 基因疗法
    • 组织工程
    • 富血小板血浆
  • 市场分析、洞察与预测：依应用分类
    • 骨科
    • 伤口护理
    • 肿瘤科
    • 罕见疾病
    • 其他
  • 市场分析、洞察与预测：依最终用户分类
    • 医院
    • 临床医师
    • 其他
  • 市场分析、洞察与预测：依区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美再生医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲再生医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区再生医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲再生医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲再生医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家/地区
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Integra LifeSciences Corporation
    • Bristol-Myers Squibb Company
    • Tissue Regenix
    • Smith &Nephew
    • MiMedx
    • Novartis AG
    • Allergan Aesthetics(AbbVie Inc.)
    • Stryker
    • American CryoStem Corporation
    • Kite(Gilead Sciences, Inc.)
    • AlloSource
    • bluebird bio, Inc.
    • CRISPR Therapeutics
    • Janssen Global Services, LLC(Johnson &Johnson Services, Inc.)
    • Tegoscience
Product Code: FBI100970

Growth Factors of regenerative medicine Market

The global regenerative medicine market is poised for exponential growth, driven by innovations in cell therapy, gene therapy, tissue engineering, and platelet-rich plasma (PRP) therapies. Regenerative medicine focuses on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. It provides potential treatments for chronic and terminal conditions such as cancers, Parkinson's disease, Alzheimer's disease, diabetes, cardiovascular disorders, and renal diseases.

According to Fortune Business Insights, the market was valued at USD 51.65 billion in 2025, expected to grow to USD 63 billion in 2026, and projected to reach USD 555.58 billion by 2034, reflecting a remarkable CAGR of 31.27% from 2026 to 2034. North America dominated the market in 2025 with a 45.38% share, fueled by technological advancements, rapid adoption of cell and gene therapies, and a supportive regulatory environment. The U.S. market is projected to grow substantially, reaching USD 184.21 billion by 2032, driven by government-backed R&D initiatives and innovative product approvals.

Market Drivers

Increasing R&D Investments and Innovative Product Launches: Governments, private players, and academic institutions are heavily investing in regenerative medicine to develop novel therapies. For instance, in July 2022, Washington University received a grant of USD 557,000 from the NHLBI to study ETRIM72 protein for regenerating vasculature and skeletal muscles in diabetic critical limb ischemia. Similarly, Wipro and Pandorum Technologies partnered in March 2022 to integrate artificial intelligence in regenerative medicine R&D, accelerating time-to-market and improving patient outcomes.

Emerging Pipeline and Clinical Candidates: Pharmaceutical and life sciences companies are broadening applications from wound care and tissue repair to cardiology, oncology, neurology, and rare diseases. In November 2023, Sysmex Corporation entered a licensing agreement with JUNTEN BIO for immune tolerance therapies, and in June 2022, CRISPR Therapeutics reported positive Phase 1 results for its allogeneic CAR-T cell therapy CTX130 targeting solid tumors. Such developments expand product adoption and accelerate market growth.

Rising Prevalence of Chronic Diseases: Increasing incidence of diabetes, cancer, cardiovascular diseases, and orthopedic conditions is creating strong demand for advanced regenerative therapies. The orthopedics segment alone is projected to hold 40.61% of the market share in 2026, as products accelerate healing and reduce pain from musculoskeletal disorders.

Market Restraints

High Treatment Costs and Limited Reimbursement: The high cost of therapies, such as stem cell treatments ranging from USD 5,000-50,000 and gene therapy like Zolgensma at USD 2.12 million, limits accessibility. Inadequate insurance coverage often forces patients to pay out-of-pocket or rely on crowdfunding, hindering adoption. Additionally, limited approved therapies for rare genetic disorders pose barriers to growth.

Market Segmentation

By Product:

  • Cell Therapy: Dominates the market with 54.87% share in 2026, widely used for autoimmune disorders, cancers, infectious diseases, and musculoskeletal injuries.
  • Gene Therapy: Highest CAGR, treating rare diseases such as Spinal Muscular Atrophy, offering targeted, effective interventions.
  • Tissue Engineering: Second-largest share, catering to wound care with scaffolds, biomatrices, and skin-like products.
  • Platelet-Rich Plasma (PRP): Smallest share but growing in orthopedics and cosmetic applications.

By Application:

  • Orthopedics: Largest segment in 2026 due to increasing bone and joint injuries.
  • Oncology: High CAGR as CAR-T therapies meet unmet needs for cancer treatment.
  • Wound Care: Benefiting from advanced bioengineered products for chronic wounds.
  • Rare Diseases: Fastest-growing segment due to limited treatment options and increasing patient population.

By End User:

  • Hospitals: Dominant with 62.54% share in 2026, driven by surgical procedures and government support.
  • Clinics: Second-largest, offering specialized regenerative medicine services.
  • Others: Include academic and research institutes, contributing moderately due to eligibility constraints.

Regional Insights

North America: Valued at USD 23.44 billion in 2025, projected to reach USD 27.06 billion by 2026, driven by RMAT approvals, technological adoption, and strong R&D infrastructure.

Europe: Second-largest market, supported by government funding and regulatory approvals. UK projected at USD 3.58 billion, Germany at USD 4.2 billion by 2026.

Asia Pacific: Fastest-growing, with Japan at USD 3.55 billion, China at USD 3.21 billion, and India at USD 2.01 billion by 2026, fueled by chronic disease prevalence, government initiatives, and rising disposable incomes.

Latin America & MEA: Slower growth due to low healthcare expenditure and limited awareness of therapies.

Competitive Landscape

Key players include Novartis AG, Zimmer Biomet, Gilead Sciences, Stryker, Integra LifeSciences, Kite (Gilead), CRISPR Therapeutics, bluebird bio, and Allergan (AbbVie). Companies are focusing on strategic acquisitions, R&D collaborations, and licensing agreements to strengthen product pipelines and expand global presence.

Recent Developments:

  • February 2024: Iovance Biotherapeutics received FDA approval for TIL therapy (AMTAGVI) for melanoma.
  • September 2023: Launch of Lynch Regenerative Medicine for advanced wound care.
  • February 2023: CSL Behring and UniQure's Hemgenix approved in Europe for hemophilia B treatment.

Conclusion

The global regenerative medicine market is set to expand from USD 51.65 billion in 2025 to USD 63 billion in 2026, reaching an impressive USD 555.58 billion by 2034 at a CAGR of 31.27%. Growth is driven by R&D investments, innovative therapies, rising chronic disease prevalence, and government support. While high costs and limited reimbursement may restrain adoption, technological advancements, regulatory approvals, and strategic collaborations position the market for transformative impact in healthcare globally.

Segmentation By Product

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Platelet Rich Plasma

By Application

  • Orthopedics
  • Wound Care
  • Oncology
  • Rare Diseases
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (By Product, By Application, By End User, By Country)
    • U.S.
    • Canada
  • Europe (By Product, By Application, By End User, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, By Application, By End User, By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, By Application, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, By Application, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Global Financing of Companies Active in Regenerative Medicine
  • 4.2. Prevalence of Chronic Diseases, By Key Countries/Regions, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, Key Players
  • 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
  • 4.6. Technological Developments in Regenerative Medicine
  • 4.7. Impact of COVID-19 on the Global Market

5. Global Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Cell Therapy
    • 5.1.2. Gene Therapy
    • 5.1.3. Tissue Engineering
    • 5.1.4. Platelet Rich Plasma
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Orthopedics
    • 5.2.2. Wound Care
    • 5.2.3. Oncology
    • 5.2.4. Rare Diseases
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Cell Therapy
    • 6.1.2. Gene Therapy
    • 6.1.3. Tissue Engineering
    • 6.1.4. Platelet Rich Plasma
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Orthopedics
    • 6.2.2. Wound Care
    • 6.2.3. Oncology
    • 6.2.4. Rare Diseases
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Cell Therapy
    • 7.1.2. Gene Therapy
    • 7.1.3. Tissue Engineering
    • 7.1.4. Platelet Rich Plasma
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Orthopedics
    • 7.2.2. Wound Care
    • 7.2.3. Oncology
    • 7.2.4. Rare Diseases
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Cell Therapy
    • 8.1.2. Gene Therapy
    • 8.1.3. Tissue Engineering
    • 8.1.4. Platelet Rich Plasma
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Orthopedics
    • 8.2.2. Wound Care
    • 8.2.3. Oncology
    • 8.2.4. Rare Diseases
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Cell Therapy
    • 9.1.2. Gene Therapy
    • 9.1.3. Tissue Engineering
    • 9.1.4. Platelet Rich Plasma
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Orthopedics
    • 9.2.2. Wound Care
    • 9.2.3. Oncology
    • 9.2.4. Rare Diseases
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Cell Therapy
    • 10.1.2. Gene Therapy
    • 10.1.3. Tissue Engineering
    • 10.1.4. Platelet Rich Plasma
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Orthopedics
    • 10.2.2. Wound Care
    • 10.2.3. Oncology
    • 10.2.4. Rare Diseases
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Integra LifeSciences Corporation
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Bristol-Myers Squibb Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Tissue Regenix
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Smith & Nephew
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. MiMedx
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Novartis AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Allergan Aesthetics (AbbVie Inc.)
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Stryker
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. American CryoStem Corporation
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Kite (Gilead Sciences, Inc.)
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. AlloSource
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. bluebird bio, Inc.
      • 11.2.12.1. Overview
      • 11.2.12.2. Products & Services
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. CRISPR Therapeutics
      • 11.2.13.1. Overview
      • 11.2.13.2. Products & Services
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)
    • 11.2.14. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
      • 11.2.14.1. Overview
      • 11.2.14.2. Products & Services
      • 11.2.14.3. SWOT Analysis
      • 11.2.14.4. Recent Developments
      • 11.2.14.5. Strategies
      • 11.2.14.6. Financials (Based on Availability)
    • 11.2.15. Tegoscience
      • 11.2.15.1. Overview
      • 11.2.15.2. Products & Services
      • 11.2.15.3. SWOT Analysis
      • 11.2.15.4. Recent Developments
      • 11.2.15.5. Strategies
      • 11.2.15.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 2: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 3: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 4: Global Regenerative Medicine Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 5: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 6: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 7: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 8: North America Regenerative Medicine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 10: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 12: Europe Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 13: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 14: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 15: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 16: Asia Pacific Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 17: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 18: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 20: Latin America Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 24: Middle East & Africa Regenerative Medicine Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Regenerative Medicine Market Value Share (%), By Product, 2025 & 2034
  • Figure 2: Global Regenerative Medicine Market Value Share (%), By Application, 2025 & 2034
  • Figure 3: Global Regenerative Medicine Market Value Share (%), By End User, 2025 & 2034
  • Figure 4: Global Regenerative Medicine Market Value (USD billion), By Region, 2025 & 2034
  • Figure 5: North America Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 6: North America Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 7: North America Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 8: North America Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 9: North America Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 10: North America Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 11: North America Regenerative Medicine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 12: North America Regenerative Medicine Market Value Share (%), by Country, 2025
  • Figure 13: Europe Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 14: Europe Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 15: Europe Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 16: Europe Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 17: Europe Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 18: Europe Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 19: Europe Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 20: Europe Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 21: Asia Pacific Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 22: Asia Pacific Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 23: Asia Pacific Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 24: Asia Pacific Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 25: Asia Pacific Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 26: Asia Pacific Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 27: Asia Pacific Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 28: Asia Pacific Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 29: Latin America Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 30: Latin America Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 31: Latin America Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 32: Latin America Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 33: Latin America Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Latin America Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 35: Latin America Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 36: Latin America Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 37: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Product, 2025 & 2034
  • Figure 38: Middle East & Africa Regenerative Medicine Market Value Share (%), by Product, 2025
  • Figure 39: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Middle East & Africa Regenerative Medicine Market Value Share (%), by Application, 2025
  • Figure 41: Middle East & Africa Regenerative Medicine Market Value (USD billion), by End User, 2025 & 2034
  • Figure 42: Middle East & Africa Regenerative Medicine Market Value Share (%), by End User, 2025
  • Figure 43: Middle East & Africa Regenerative Medicine Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 44: Middle East & Africa Regenerative Medicine Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 45: Global Regenerative Medicine Market Share (%), By Company, 2025